Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Comment by prokofievon Apr 05, 2018 1:11pm
172 Views
Post# 27837036

RE:drip drip

RE:drip dripI don't care much, I'll be significantly adding to my position the day the deal is announced, having sold part of my holdings much higher and not having bought since.

From my perspective it is a no brainer. Stock has been under pressure for over a month now because of this equity raise. You are likely to see several catalysts play out shortly (next 2-3 months) after the raise taking it back to $15+... And then its off to the races.

I agree, its been a long and bumpy ride. While I have been a lot of money in this name, I certainly look forward to a larger payout. Once the deal closes and I have built my position, I will most likely share my short-term and long-term price targets along with the rationale with the board. 

Almost there!

Prokofiev 

 

rdwww wrote: financing at $11? or 2.20 pre consolidate? which is higher than the $1.75 done last June I guess


Bullboard Posts